Xenon Pharmaceuticals Inc.
XENE
Health Care
2
exclusion reasons
1 theme
Xenon Pharmaceuticals Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline requires animal testing to meet regulatory requirements for product approval. The company's annual reports explicitly state that its preclinical studies are subject to the U.S. Animal Welfare Act, and that sponsors must submit the results of these tests to regulatory authorities. This indicates animal testing is an integral, non-optional component of its core business model.
The company is flagged by Cruelty Free Investors for exploiting animals, a designation applied to firms engaged in animal testing. As a pharmaceutical developer, Xenon's research and development activities inherently involve animal models to assess the safety and efficacy of its drug candidates prior to human clinical trials. The available evidence does not detail the scale or specifics of its animal testing operations, but its regulatory disclosures confirm this practice is a fundamental part of its operations.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company whose business model is predicated on animal testing for regulatory compliance and product development. The company’s pipeline of novel neurological therapeutics, including its lead candidate NBI-921352 for focal onset seizures, requires extensive nonclinical laboratory tests and animal studies to advance through the FDA approval process. Published research on its compounds explicitly details the licensing and use of genetically modified mouse models, such as the NaV1.6 N1768D mouse, for pharmacological characterization.
All of Xenon’s drug candidates are in pre-clinical or clinical development, a phase where animal data is mandatory for regulatory submissions. The company’s own annual report notes that long-term pre-clinical testing includes “animal tests of reproductive [adverse events].” As a pharmaceutical company with no marketed products, its entire research and development operation is built on animal experimentation to establish safety and efficacy before human trials.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.